Articles On Genetic Technologies (ASX:GTG)

RHY’s geneType twice as effective at identifying women with elevated ovarian cancer risk than using clinical or genetic information alone Peer-reviewed study validates Rhythm’s ovarian cancer risk prediction model Cross-validation across t...

October marks Global Breast Cancer Awareness Month with several ASX companies working to advance early detection and treatments for better outcomes Imagion’s first-of-its-kind imaging agent tech MagSense uses targeted nanoparticles to enha...

Rhythm enters co-marketing deal with geneType to be available on Know Your Lemons mobile app Partnership aligns with Breast Cancer Awareness Month in October, supporting proactive healthcare for women Reaching hundreds of thousands of wome...

Artrya shares surge up to 42% on FDA clearance of the company’s Salix Coronary Plaque device Sonic Healthcare joins CSL in the healthcare sin bin Universal Biosensors calls in the corporate undertakers   Artrya (ASX:AYA) has won US Food a...

 Pro Medicus shares surge up to 7% on record revenue and earnings Tetratherix pockets $3.3 million, while Rhythm girds for a raising CEO oration inspires Starpharma share run   The $32 billion market cap ProMedicus (ASX:PME) has drawn the...

Bioxyne stars with a 720% gain in the 2024-25 year Paradigm shares soar 34% after $41 million convertible note deal Biotechs turn to debt funding The ASX biotech sector’s best EOFY performer has come from left field: the local and Europ...

ASX surges 1pc as Iran and Israel approach ceasefire Materials and financials lead gains, adding more than 1.8pc each Energy sector drags, shedding 3.89pc as oil slumps   ASX on the rise as missiles keep firing The ASX shot up 1% today, w...

Rhythm receives reinstatement of NATA accreditation for Genetype risk assessment portfolio Genetype is a sophisticated genetic risk assessment testing platform for various diseases Reinstatement is a key milestone for securing ColoSTAT acc...

Rhythm Biosciences has expanded its original remit of bowel cancer to diagnosing other cancers early in the piece The company late last year acquired the Genetype platform from the administrators of Genetic Technologies Rhythm is developin...

Little Green Pharma reports record revenue and a return to profits Botanix raises $48 million of debt for its anti-sweating drug, Sofdra The DNA of Genetic Technologies soon will be … financial advice   Little Green Pharma’s (ASX:LGP) Eur...

Surgical probe steriliser Nanosonics flags robust December half numbers The biotech quarterlies are tricking in – and there’s mixed news Paradigm shares are worth twice as much as their current price, says Pitt Street Partners   Nanosonic...

Melbourne-based bowel cancer diagnostics developer Rhythm Biosciences (ASX: RHY) has acquired the GeneType disease prediction business for $625,000 from Genetic Technologies (ASX: GTG), which entered administration last month after falling...

From artificial intelligence (A.I) to zygotes, the biotech sector this year delivered the A to Z of excitement, intrigue, occasional disappointment and downright disaster. His virtual stethoscope on hand, Dr Boreham was on duty to diagnose...

Opyl has partnered to form the ‘world’s first’ AI-driven biotech fund Visioneering sees a brighter future – elsewhere – but its shares tumble  Cyclopharm breathes easy after decent lung transplant trial results   Who needs fund managers t...

The S&P/ASX 200 Health Care Index rose 2.89% in November as momentum returned to the sector Health cryogenic services company Vitrafy and nerve-repair biotech Renerve debuted on the ASX  Paradigm Biopharmaceuticals rose 151% in Novembe...

ASX healthcare stocks underperform but optimism grows Uscom, Respiri and Hitiq report mixed results Artrya and Nyrada make key clinical advances   The S&P/ASX 200 Health Care [XHJ] index was down 0.9% gain in October. For the year, th...

Healthcare stocks are doing relatively well globally in 2024
 The sector could see more recovery as Fed cuts rates
 How ASX biotechs performed in the month of September   The S&P 500 Health Care Index, a key world benchmark for health...

The ASX200 closed down 0.3% at 7,988 points. The US Presidential debate between Trump and Harris had little affect on the Aussie market, but did see US futures fall slightly lower. Eight out of the eleven sectors were down, with Finan...

  To register for Friday's webinar click here. DroneShield Ltd (ASX:DRO) has announced it has received a repeat order of $3.1 million from a U.S. Government customer for a number of its counterdrone (C-UxS) systems. The delivery is expected...

ASX health stocks down in August and trail the broader market in 2024 CSL up 6,000pc since listing; sector outpaced benchmark 10x since 2006 AI is revolutionising healthcare, boosting diagnosis and treatment   The ASX Healthcare Index (AS...

Genetic Technologies Limited (ASX: GTG) is set to boost access to its geneType personalised risk tests – which enable assessment for breast cancer, colorectal cancer, ovarian cancer, prostate cancer, coronary artery disease, among others –...

The ASX dropped, dragged down by Real Estate and Mining stocks Qantas cuts former CEO’s compensation by $9.3m Fears of a US recession are growing, with the Sahm Rule signalling potential trouble   A selloff in Real Estate and Mining stock...

S&P/ASX 200 Health Care index up 5pc in July, 9.5pc YTD Health sector gains momentum with expected Fed rate cuts; ResMed seen as a strong buy And ASX healthcare winners and losers in July   The S&P/ASX 200 Health Care index [XHJ]...

S&P/ASX 200 had its best month of the year in July finishing up 4% to record high S&P Dow Jones Indices says large cap companies continued to lead the market in July Consumer discretionary and real estate topped July sector leaders...

The EMA has rejected the Alzheimer’s drug Leqembi, developed by Eisai and Biogen There is one ASX-listed company that collaborates with Eisai We take a look at the best performing ASX health stocks in the past month   In a major blow for...

GTG to pivot to US with a more streamlined, efficient business model Pacific Edge says it’s still waiting on Medicare decision in the US   GTG pivots to the US Genetic Technologies (ASX:GTG) said it was undergoing a major restructuring to...

ASX 200 punches through 8,000 on Monday All sectors higher Small cap miners led by Aldoro Resources Local markets surged into record territory on Monday, pushing through the 8,000 threshold as traders played catch up to Wall Street’s r...

The ASX Health Care index saw a 4% increase in June Growth was driven by CSL and Cochlear Best biotechs in June were Actinogen, Optiscan and EZZ Life Science, amongst others    The S&P/ASX 200 Health Care index [XHJ] saw a 4% increase...

Genomics-based testing producer Genetic Technologies Ltd (ASX:GTG) believes its geneType Risk Assessment tests – sold in Australia and the United States – have the potential to clearly identify people with serious risk of disease or cancer,...

Aussie shares rally Rate sensitive stocks gain, led by Tech FTL soars on Newfoundland deal   Aussie shares climbed strongly on Thursday closing above 7,820 as major global central banks began to cut interest rates and in the US, the S&amp...

Good morning, and welcome to Stockhead’s Top 10 at shortly-before-11-ish, which is meant to highlight the best (and sometimes worst) performing ASX stocks in morning trade using live data, to provide a short, sharp update to help frame the...

 S&P/ASX 200 Health Care closed flat in May 2024 brings challenges, but hopes are high for biotech stocks We take a look at the ASX biotech winners for the month   The  S&P/ASX 200 Health Care [XHJ] closed flattish for the month o...

ASX down by -0.5pc, weekly loss surpasses 2pc Mining, Energy stocks main laggards today Asian stocks also decline, North Korea fires ballistic missiles   The ASX200 index has dipped lower by -0.5% on Thursday, taking its weekly loss to mo...

Cleo jumps 30pc after publishing study results Cleo Diagnostics (ASX:COV) surged nearly 30% this morning after announcing a breakthrough article on its blood test for early ovarian cancer detection. The article, entitled ‘Utility of a Multi...

Stockhead’s Top 10 at 10, published at ~10.40am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

Research shows Alzheimer’s is entirely preventable A poor diet and bad gut bacteria can increase the risk of dementia We look at the best performing ASX stocks over the past month    The phrase ‘you are what you eat’ was coined almost a c...

ASX Health sector was in correction territory in April Why is the health sector different from other sectors? We look at the best performing ASX health stocks for the month   The S&P/ASX 200 Health Care [XHJ] had a soft month in April...

There’s been a breakthrough in acne treatment Scientists have found a way to use skin bacteria to control sebum production We look at the best and worst performing ASX health stocks in the past month   Scientists have made a significant b...

Stockhead’s Top 10 at 10, published at ~10.40am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

Dual ASX and NASDAQ smallcap Genetic Technologies (ASX:GTG) has announced its launch of a breast cancer imaging program across three US clinics in NY, Miami and Houston, Texas. The program will integrate GTG’s “geneType” saliva-based and...

The ASX200 is down nearly half a per cent – beating futures predictions. Aside from health care and real estate, most sectors have been in the red so far. In this bulletin, we’ll look at news from Fisher & Paykel Healthcare Corpor...

Genetic Technologies (ASX:GTG), known for its expertise in genomics-based testing, has introduced its most advanced risk assessment test for serious diseases – including breast and ovarian cancer. This new test builds upon the success of it...

Molecular diagnostics company Genetic Technologies (ASX: GTG) has announced a major breakthrough in risk assessment tests for serious diseases. The new GeneType technology builds on the success of the company’s comprehensive hereditary brea...

ASX Health Index down -1.5% for February 76 biotechs rose, and 78 fell during the month But essentially, biotech is a long term game for investors   The S&P/ASX 200 Health Care [XHJ] struggled in February, finishing -1.5% lower and tr...

Good morning, and welcome to Stockhead’s Top 10 at shortly-before-11-ish, which is meant to highlight the best (and sometimes worst) performing ASX stocks in morning trade using live data, to provide a short, sharp update to help frame the...

Viking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on pancreatic cancer results We look at the recent best performing ASX health stocks   There were a couple of big news from the world of biotec...

Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

Good morning, and welcome to Stockhead’s Top 10 at shortly-before-11-ish, to highlight the best (and sometimes worst) performing ASX stocks in morning trade using live data, to provide a short, sharp update to help frame the trading day by...

The ASX benchmark has closed slightly higher on Monday Energy Sector gains after oil prices rose over the weekend Small caps led Killi Resources, Nyrada and Viridis Mining   The Aussie sharemarket has ended the opening salvo of the week...

The ASX benchmark has closed slightly lower on Friday Losses across the Energy Sector weighed Small caps led ID8   The Aussie sharemarket has ended lower on Friday, driven to a small disgrace by the ongoing declines in oil prices – down...